Royalty Pharma (RPRX)

• Market cap: $24.1B
• 1 day: -1.09%
• 5 days: -1.95%
• 1 month: 2.69%
• 3 months: 17.72%
• 6 months: 40.85%
• Year to date: 39.66%
• 1 year: 54.62%
• 5 years: 23.28%
• 10 years: 21.96%
• Sector: Healthcare
• Industry: Biotechnology

About: Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.

Employees: 100